Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind study of azvudine + tenofovir disoproxil fumarate + efavirenz in treatment-naive HIV-1 infection
CTR20220295Phase 3Active
- Sponsor
- Zhengzhou University
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of azvudine in Human immunodeficiency virus infection type 1, sponsored by Zhengzhou University. Started Jun 2022; status: active.
02
Drugs
azvudine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on CTR20220295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220295.